过氧化物酶体增殖物活化受体-γ与库欣病的治疗  

Peroxisome proliferator-activated receptor-γ in the treatment of Cushing＇s disease

作　　者：顾生虹[1] 宁光[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院内分泌代谢科,上海市内分泌代谢病临床医学中心,200025

出　　处：《国际内分泌代谢杂志》2007年第3期206-208,共3页International Journal of Endocrinology and Metabolism

摘　　要：手术切除垂体促肾上腺皮质激素（ACTH）肿瘤是库欣病的最佳治疗手段,但长期的治愈率并不令人满意。过氧化物酶体增殖物活化受体-γ在人垂体ACTH瘤上的大量表达使之成为库欣病药物治疗的新靶点。其激动剂如噻唑烷二酮类药物在离体试验中促进垂体ACTH肿瘤细胞的凋亡,抑制小鼠ACTH肿瘤的生长,降低血ACTH及皮质醇的分泌,同时改善代谢紊乱。但在临床研究中噻唑烷二酮类药物对库欣病患者的疗效尚不肯定,仍需进一步验证。Surgical excision of adrenocorticotrophie hormone（ACTH）-seereting pituitary tumor is the optimal therapy for Cushing＇s disease. However, the long-term cure rate is not satisfactory. The abundant expression of peroxisome proliferator-activated receptor-γ（PPAR-γ） in human ACTH-secreting tumors makes it a novel target in the treatment of Cushing＇s disease. PPAR-γ agonists such as thiazolidinedione are able to induce apoptosis in corticotroph tunaor cell in vitro, inhibit pituitary tumor growth, suppress the secretion of ACTH and corticosterone in the mice model and improve the metabolic effect. But the therapeutic effect in the clinical study is not sure, which needs more investigation.

关 键 词：库欣病 过氧化物酶体增殖物活化受体-γ 噻唑烷二酮类 

分 类 号：R5[医药卫生—内科学]